Competition Commission of India (CCI) has cleared IMCD India's acquisition of an additional 30% stake in Signet Excipients, a pharmaceutical excipients company.
New Delhi, Jan 9 (PTI) Fair trade regulator Competition Commission of India (CCI) on Tuesday said it has cleared IMCD India Pvt Ltd's acquisition of an additional 30 per cent equity stake in Signet Excipients.
Signet Excipients is engaged in the business of sales, marketing, distributing, importing, or exporting of excipients used for pharmaceuticals, food, API products, and other related products for pharmaceutical formulation.
The proposed combination relates to the acquisition of the remaining 30 per cent equity stake in Signet Excipients Private Ltd by IMCD India Pvt Ltd by exercising a call option, according to a release.
IMCD India is an indirect wholly-owned subsidiary of Rotterdam-based IMCD NV.
It is engaged in sales, marketing, and distribution of specialty chemicals, including food and pharma ingredients in the Indian market.
Signet Excipients is jointly controlled by IMCD and its promoters. Currently, IMCD India and the promoters hold 70 per cent and 30 per cent of the equity stake in Signet Excipients, respectively.
The deals beyond a certain threshold require approval from the regulator, which keeps a tab on unfair business practices as well as promotes fair competition in the marketplace.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback